Research Analysts Set Expectations for Brainsway Q3 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Analysts at Northland Capmk lifted their Q3 2025 earnings per share (EPS) estimates for Brainsway in a research report issued to clients and investors on Wednesday, August 13th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of $0.10 per share for the quarter, up from their previous forecast of $0.06. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. Northland Capmk also issued estimates for Brainsway’s FY2026 earnings at $0.40 EPS.

Brainsway (NASDAQ:BWAY) last posted its earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.03. Brainsway had a return on equity of 8.97% and a net margin of 11.60%. The company had revenue of $12.63 million for the quarter, compared to analyst estimates of $12.34 million.

A number of other equities research analysts have also weighed in on BWAY. Wall Street Zen lowered Brainsway from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. HC Wainwright restated a “buy” rating and set a $17.00 price target (up previously from $16.00) on shares of Brainsway in a research note on Thursday. Finally, Northland Securities boosted their price target on Brainsway from $15.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday.

Brainsway Price Performance

BWAY opened at $12.98 on Friday. Brainsway has a 1 year low of $7.06 and a 1 year high of $13.65. The firm has a market capitalization of $245.32 million, a PE ratio of 49.92 and a beta of 1.42. The business’s 50-day moving average is $12.08 and its two-hundred day moving average is $10.53.

Hedge Funds Weigh In On Brainsway

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP raised its stake in Brainsway by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after acquiring an additional 1,786 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in Brainsway by 14.6% in the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after buying an additional 2,446 shares during the last quarter. Huntleigh Advisors Inc. boosted its position in Brainsway by 5.7% in the second quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock valued at $1,018,000 after buying an additional 4,143 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in Brainsway in the fourth quarter valued at approximately $44,000. Finally, Raymond James Financial Inc. purchased a new stake in Brainsway in the second quarter valued at approximately $85,000. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.